scholarly journals Predicting Drug Targets and Biomarkers of Cancer via Genome-Scale Metabolic Modeling

2012 ◽  
Vol 18 (20) ◽  
pp. 5572-5584 ◽  
Author(s):  
Livnat Jerby ◽  
Eytan Ruppin
2015 ◽  
Author(s):  
Jean F. Challacombe

AbstractThe intracellular pathogenBurkholderia pseudomallei,which is endemic to parts of southeast Asia and northern Australia, causes the disease melioidosis. Although acute infections can be treated with antibiotics, melioidosis is difficult to cure, and some patients develop chronic infections or a recrudescence of the disease months or years after treatment of the initial infection.B. pseudomalleistrains have a high level of natural resistance to a variety of antibiotics, and with limited options for new antibiotics on the horizon, new alternatives are needed. The aim of the present study was to characterize the metabolic capabilities ofB. pseudomallei, identify metabolites crucial for pathogen survival, understand the metabolic interactions that occur between pathogen and host cells, and determine if metabolic enzymes produced by the pathogen might be potential antibacterial targets. This aim was accomplished through genome scale metabolic modeling under different external conditions: 1) including all nutrients that could be consumed by the model, and 2) providing only the nutrients available in culture media. Using this approach, candidate chokepoint enzymes were identified, then knocked outin silicounder the different nutrient conditions. The effect of each knockout on the metabolic network was examined. When five of the candidate chokepoints were knocked outin silico, the flux through theB. pseudomalleinetwork was decreased, depending on the nutrient conditions. These results demonstrate the utility of genome-scale metabolic modeling methods for drug target identification inB. pseudomallei.


Metabolites ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 14
Author(s):  
Anurag Passi ◽  
Juan D. Tibocha-Bonilla ◽  
Manish Kumar ◽  
Diego Tec-Campos ◽  
Karsten Zengler ◽  
...  

Genome-scale metabolic models (GEMs) enable the mathematical simulation of the metabolism of archaea, bacteria, and eukaryotic organisms. GEMs quantitatively define a relationship between genotype and phenotype by contextualizing different types of Big Data (e.g., genomics, metabolomics, and transcriptomics). In this review, we analyze the available Big Data useful for metabolic modeling and compile the available GEM reconstruction tools that integrate Big Data. We also discuss recent applications in industry and research that include predicting phenotypes, elucidating metabolic pathways, producing industry-relevant chemicals, identifying drug targets, and generating knowledge to better understand host-associated diseases. In addition to the up-to-date review of GEMs currently available, we assessed a plethora of tools for developing new GEMs that include macromolecular expression and dynamic resolution. Finally, we provide a perspective in emerging areas, such as annotation, data managing, and machine learning, in which GEMs will play a key role in the further utilization of Big Data.


2021 ◽  
Author(s):  
Oveis Jamialahmadi ◽  
Ehsan Salehabadi ◽  
Sameereh Hashemi-Najafabadi ◽  
Ehsan Motamedian ◽  
Fatemeh Bagheri ◽  
...  

Abstract Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide. Often this hepatic cancer is associated with fatty liver disease and insulin resistance with genetic predisposition are its major driver. Genome-scale metabolic modeling (GEM) is a promising approach to understand cancer metabolism and to identify new drug targets. Here, we used TRFBA-CORE, an algorithm generating a model using key growth-correlated reactions. Specifically, we generated a HepG2 cell-specific GEM by integrating this cell line transcriptomic data with a generic human metabolic model to predict potential drug targets for hepatocellular carcinoma (HCC). A total of 108 essential genes for growth were predicted by TRFBA-CORE. These genes were enriched for metabolic pathways involved in cholesterol, sterols and steroids biosynthesis. Furthermore, we silenced a predicted essential gene, 11-beta dehydrogenase hydroxysteroid type 2 (HSD11B2), in HepG2 cells resulting in a reduction in cell viability. To further identify novel potential drug targets in HCC, we examined the effect of 9 drugs targeting the essential genes, and observed that most drugs inhibited the growth of HepG2 cells. Interestingly, some of these drugs in this model performed better than Sorafenib, the first line therapeutic against HCC.


eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
Keren Yizhak ◽  
Edoardo Gaude ◽  
Sylvia Le Dévédec ◽  
Yedael Y Waldman ◽  
Gideon Y Stein ◽  
...  

Utilizing molecular data to derive functional physiological models tailored for specific cancer cells can facilitate the use of individually tailored therapies. To this end we present an approach termed PRIME for generating cell-specific genome-scale metabolic models (GSMMs) based on molecular and phenotypic data. We build >280 models of normal and cancer cell-lines that successfully predict metabolic phenotypes in an individual manner. We utilize this set of cell-specific models to predict drug targets that selectively inhibit cancerous but not normal cell proliferation. The top predicted target, MLYCD, is experimentally validated and the metabolic effects of MLYCD depletion investigated. Furthermore, we tested cell-specific predicted responses to the inhibition of metabolic enzymes, and successfully inferred the prognosis of cancer patients based on their PRIME-derived individual GSMMs. These results lay a computational basis and a counterpart experimental proof of concept for future personalized metabolic modeling applications, enhancing the search for novel selective anticancer therapies.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Joshua E. Lewis ◽  
Melissa L. Kemp

AbstractResistance to ionizing radiation, a first-line therapy for many cancers, is a major clinical challenge. Personalized prediction of tumor radiosensitivity is not currently implemented clinically due to insufficient accuracy of existing machine learning classifiers. Despite the acknowledged role of tumor metabolism in radiation response, metabolomics data is rarely collected in large multi-omics initiatives such as The Cancer Genome Atlas (TCGA) and consequently omitted from algorithm development. In this study, we circumvent the paucity of personalized metabolomics information by characterizing 915 TCGA patient tumors with genome-scale metabolic Flux Balance Analysis models generated from transcriptomic and genomic datasets. Metabolic biomarkers differentiating radiation-sensitive and -resistant tumors are predicted and experimentally validated, enabling integration of metabolic features with other multi-omics datasets into ensemble-based machine learning classifiers for radiation response. These multi-omics classifiers show improved classification accuracy, identify clinical patient subgroups, and demonstrate the utility of personalized blood-based metabolic biomarkers for radiation sensitivity. The integration of machine learning with genome-scale metabolic modeling represents a significant methodological advancement for identifying prognostic metabolite biomarkers and predicting radiosensitivity for individual patients.


Microbiology ◽  
2014 ◽  
Vol 160 (6) ◽  
pp. 1252-1266 ◽  
Author(s):  
Hassan B. Hartman ◽  
David A. Fell ◽  
Sergio Rossell ◽  
Peter Ruhdal Jensen ◽  
Martin J. Woodward ◽  
...  

Salmonella enterica sv. Typhimurium is an established model organism for Gram-negative, intracellular pathogens. Owing to the rapid spread of resistance to antibiotics among this group of pathogens, new approaches to identify suitable target proteins are required. Based on the genome sequence of S. Typhimurium and associated databases, a genome-scale metabolic model was constructed. Output was based on an experimental determination of the biomass of Salmonella when growing in glucose minimal medium. Linear programming was used to simulate variations in the energy demand while growing in glucose minimal medium. By grouping reactions with similar flux responses, a subnetwork of 34 reactions responding to this variation was identified (the catabolic core). This network was used to identify sets of one and two reactions that when removed from the genome-scale model interfered with energy and biomass generation. Eleven such sets were found to be essential for the production of biomass precursors. Experimental investigation of seven of these showed that knockouts of the associated genes resulted in attenuated growth for four pairs of reactions, whilst three single reactions were shown to be essential for growth.


2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Pouyan Ghaffari ◽  
Adil Mardinoglu ◽  
Anna Asplund ◽  
Saeed Shoaie ◽  
Caroline Kampf ◽  
...  

2020 ◽  
Vol 8 (11) ◽  
pp. 1793
Author(s):  
Jinxin Zhao ◽  
Yan Zhu ◽  
Jiru Han ◽  
Yu-Wei Lin ◽  
Michael Aichem ◽  
...  

Multidrug-resistant (MDR) Acinetobacter baumannii is a critical threat to human health globally. We constructed a genome-scale metabolic model iAB5075 for the hypervirulent, MDR A. baumannii strain AB5075. Predictions of nutrient utilization and gene essentiality were validated using Biolog assay and a transposon mutant library. In vivo transcriptomics data were integrated with iAB5075 to elucidate bacterial metabolic responses to the host environment. iAB5075 contains 1530 metabolites, 2229 reactions, and 1015 genes, and demonstrated high accuracies in predicting nutrient utilization and gene essentiality. At 4 h post-infection, a total of 146 metabolic fluxes were increased and 52 were decreased compared to 2 h post-infection; these included enhanced fluxes through peptidoglycan and lipopolysaccharide biosynthesis, tricarboxylic cycle, gluconeogenesis, nucleotide and fatty acid biosynthesis, and altered fluxes in amino acid metabolism. These flux changes indicate that the induced central metabolism, energy production, and cell membrane biogenesis played key roles in establishing and enhancing A. baumannii bloodstream infection. This study is the first to employ genome-scale metabolic modeling to investigate A. baumannii infection in vivo. Our findings provide important mechanistic insights into the adaption of A. baumannii to the host environment and thus will contribute to the development of new therapeutic agents against this problematic pathogen.


Sign in / Sign up

Export Citation Format

Share Document